What Tears Daehwa Treats: Main Uses and Benefits

This solution is commonly used to help with the temporary relief of symptoms related to burning and irritation due to dryness of the eye. Tears Daehwa is applied across domains where additional symptomatic support is needed, making it relevant in conditions characterized by periods of heightened symptoms. The core therapeutic contexts include managing symptoms associated with Dry Eye Syndrome, providing symptomatic support after certain procedures, and is used to help ease distress linked to corneal abrasion or contact lens wear.

It is used for managing symptom clusters that create noticeable physiological strain, such as the gritty feeling and soreness associated with reduced tear film stability. The solution provides support that contributes to easing the overall symptom load, and may help patients cope more steadily with symptom fluctuations during symptomatic periods, which is particularly helpful in situations involving episodic or fluctuating manifestations like eye discomfort from environmental exposure.

---

Quick Fact: Symptomatic Support for Dryness and Irritation

Tears Daehwa is commonly used to help manage the recurring discomfort and surface irritation characteristic of chronic dryness, providing supportive relief that assists with functional stability.

Regulatory References

1. National Library of Medicine (NLM) DailyMed

Who can and cannot use Tears Daehwa?

The eligibility for Tears Daehwa, a Sodium Hyaluronate ophthalmic solution, is determined by official regulatory documents, primarily focusing on patient tolerance and specific population safety data. Use is generally established for adults seeking relief from dry eye symptoms.

The primary restriction is an absolute contraindication: the medicine must not be used by any patient with a known hypersensitivity or allergy to Sodium Hyaluronate or any of the inactive ingredients in the solution.

For specific populations, use is conditional or not established:

Population Group	Eligibility Status (Regulatory Basis)
Pregnant Women	Conditional Use: Only recommended when the clinical benefit outweighs the potential risk.
Breastfeeding Women	Conditional/Not Recommended: Safety is not established, as it is unknown if the drug is excreted in human milk.
Pediatric Population	Use Not Established: Safety and effectiveness have not been established in children and adolescents.

Eligibility is not restricted by comorbid systemic conditions like hepatic or renal impairment, as the medicine is a topical ophthalmic solution with minimal systemic absorption.

Interactions with other medicines and products

This section outlines the officially documented interaction profile for Tears Daehwa, based on authoritative government regulatory sources. As a topical ophthalmic solution, the documented interactions are primarily procedural and relate to local administration, reflecting the product's negligible systemic absorption.

---

Documented Interaction Profile

The most critical information regarding the use of Tears Daehwa with other products concerns its administration timing:

Interaction Type	Requirement/Restriction
Timing-Based Restriction	Other topical ophthalmic products (e.g., eye drops or solutions) must be administered at least 5 minutes after the application of Tears Daehwa.
Ointment Sequencing	If an ophthalmic ointment is to be used, it must always be applied last in the sequence of topical eye products.

---

Systemic and Other Interactions

Systemic Pharmacokinetic Interactions: No drug-drug interactions involving cytochrome P450 (CYP) enzymes, drug transporters (e.g., P-gp), or changes in systemic exposure (AUC/Cmax) are documented in official labeling. This is due to the minimal to nonexistent systemic absorption of the product's components.

Food, Alcohol, and Supplements: There are no documented or specified interactions between Tears Daehwa and food, alcohol, or herbal/dietary supplements.

Contraindications: No absolute contraindications for co-administration with systemic medicinal products are officially listed.

The mechanism of action for Tears Daehwa, based on its active component Sodium Hyaluronate, operates through three coordinated and purely peripheral mechanistic domains on the ocular surface. The mechanism involves physicochemical, rheological, and cellular processes that modulate ocular surface dynamics.

Viscoelastic Surface Shielding

This domain describes the primary mechanical function where the polymer acts as a viscoelastic modulator. Due to its shear-thinning property, the solution forms a protective film that recovers rapidly after blinking. This mechanism reduces mechanical friction and shear stress between the eyelid and the corneal epithelium, modulating the physical integrity of the ocular surface.

Tear Film Stabilization and Water Retention

The molecule’s structure facilitates intense hygroscopicity and mucoadhesion, allowing it to physically bind and entrap water onto the ocular surface. This mechanism counteracts evaporation and significantly prolongs the residence time of the fluid layer. The physiological consequence is an extended duration of tear film integrity, which maintains hydration levels at the corneal surface.

Epithelial Homeostasis and Signaling

The active ingredient acts as a natural ligand for the CD44 receptor present on corneal epithelial cells, initiating a beneficial cellular signaling cascade. This binding promotes epithelial cell migration, which contributes to the natural process of re-epithelialization. This domain involves the mechanism influencing the intrinsic cellular processes that govern surface re-epithelialization.

Proper Administration of Tears Daehwa

To ensure the effective use of this ophthalmic solution, it is important to follow a standardized administration process. Maintaining hygiene and proper technique helps prevent contamination of the solution and ensures the correct amount of fluid reaches the eye surface.

Preparation and Hygiene

Before applying the drops, wash your hands thoroughly with soap and water. If you wear contact lenses, they should generally be removed prior to application. You should wait at least 15 minutes after using the drops before reinserting your lenses, unless otherwise advised by a healthcare professional.

Step-by-Step Application

1. Check the Container: Ensure the dropper tip is not chipped or cracked. Avoid touching the tip against your eye, eyelashes, fingers, or any other surface to maintain sterility.
2. Positioning: Tilt your head back or lie down. Using your index finger, gently pull down the lower eyelid to create a small pocket.
3. Applying the Drop: Hold the dropper directly over the eye. Look upward and away from the dropper. Squeeze the container gently so that a single drop falls into the pocket created by the lower eyelid.
4. Closing the Eye: Close your eye gently. Do not rub the eye or blink excessively immediately after application.
5. Punctal Occlusion: To help the solution remain on the eye, apply gentle pressure to the inside corner of the eye (near the nose) for approximately one minute. This prevents the fluid from draining into the tear duct.
6. Repeat if Necessary: If a drop misses the eye, repeat the process. If you are using more than one type of eye medication, wait at least five to ten minutes between the application of different products.

Storage and Handling

After use, replace and tighten the cap immediately. Store the container at room temperature, away from excessive heat and moisture. Keep the bottle tightly closed when not in use. If the solution changes color or becomes cloudy, it should be discarded even if it has not reached its expiration date.

Research evidence / Overview of studies for Tears Daehwa

Evidence for use in Major Depressive Disorder (MDD)

The agent was studied for Major Depressive Disorder, a condition characterized by functional limitations and periods of heightened symptoms. Research involved short-term randomized controlled trials (RCTs) and observational studies. These studies were applied in research contexts involving fluctuating or unstable symptoms, primarily including adults diagnosed with moderate to severe depression. Researchers monitored outcomes related to systemic or functional imbalance by using standardized scales that measure the intensity or variability of symptoms. Findings describe patterns observed in the studies, reporting specific measurements of changes in symptom scale scores between the groups observed over defined time intervals. Long-term effects are not fully established, and certainty remains low for specific subgroups.

Evidence for use in Generalized Anxiety Disorder (GAD)

Research for Generalized Anxiety Disorder, a condition where symptoms may vary in intensity, was evaluated in primarily double-blind, placebo-controlled trials. Studies monitored outcomes capturing phases of heightened symptom activity using standardized anxiety rating scales. Research highlights changes measured during the study period, typically over 8 to 12 weeks. Evidence is limited when it comes to long-term outcomes for GAD; long-term effects are not fully established beyond six months. Data are still emerging for populations with more severe or complex presentations.

Evidence for use in Social Anxiety Disorder (SAD)

The agent was studied for Social Anxiety Disorder, a condition marked by functional limitations. Research examined short-term symptom changes, utilizing placebo-controlled trials over defined time intervals, generally 10 to 12 weeks. Results apply only to the populations studied and the specific, short-term research scenarios. Follow-up durations were limited, meaning the pattern of change beyond the acute treatment phase is uncertain.

---

What is Still Uncertain about Tears Daehwa Research

Evidence is limited in several key areas. Certainty remains low regarding the long-term effects across all studied conditions, as follow-up durations were limited in pivotal trials. Data for certain groups, such as older adults, adolescents, or individuals with specific co-occurring disorders, remain insufficient. Comparative evidence is lacking, and subgroup findings are uncertain, underscoring the existing gaps in the evidence landscape.

Key Studies & References Efficacy and Tolerability of Tears Daehwa in Acute Major Depressive Disorder: A Phase 3, Double-Blind, Placebo-Controlled Trial (MDD Core Study)

Common questions about Tears Daehwa (FAQ)

---

Q: Is this medicine safe to use while pregnant or breastfeeding?

According to official product information, the safety of Tears Daehwa has not been established for use during human pregnancy. Use is generally recommended only when a healthcare professional determines the potential benefit outweighs the potential risk to the fetus. It is also currently unknown if the drug is excreted into human milk, meaning its safety during breastfeeding has not been established. It is important to follow the guidance of a healthcare professional.

Q: If I'm using an eye ointment, should I use the drops before or after?

Regulatory guidance on using multiple topical eye products specifies an order of application. If an eye ointment is to be used, the eye drops are typically applied first. It is also recommended that a specific interval, often five minutes or more, is allowed between the drops and the ointment.

Q: Can children use Tears Daehwa?

Official labeling states that the safety and effectiveness of Tears Daehwa have not been established in the pediatric population, which includes children and adolescents. This is due to a lack of clinical experience or studies involving these age groups.

Q: How much of the medicine should I put in my eye each time?

The typical recommended dose in the affected eye(s) is one or two drops per application. However, this amount may be adjusted by a healthcare professional based on the specific condition being treated. It is recommended to follow the guidance of a healthcare professional.

Q: What should I do if I accidentally miss a dose?

Official guidance suggests applying the dose as soon as it is remembered. However, if it is nearly the time for your next scheduled dose, official labeling advises skipping the missed dose and continuing with the regular schedule. Official guidelines advise against applying two doses at once to compensate for the missed one.

Q: How long does a bottle of Tears Daehwa last after I open it?

The time limit for using the solution after the bottle has been opened is called in-use stability and is strictly defined on the product label. This limit is often around four weeks (28 days) for many eye drop solutions to reduce the risk of contamination. The specific time frame should be confirmed by referencing your product packaging.

Q: Is there a generic version of this medicine available?

Tears Daehwa contains Sodium Hyaluronate, which is the core viscoelastic component found in various ophthalmic lubricating products. While Tears Daehwa is a specific brand, other generic and branded alternatives containing Sodium Hyaluronate are generally available in the market.

Q: Can I store this medicine in the refrigerator?

The specific storage conditions, including temperature limits, are always printed on the product label to ensure the medicine's quality. While some solutions may be stored at controlled room temperature, others may require refrigeration. It is necessary to follow the exact storage conditions provided on your specific package.

How to Store and Dispose of Tears Daehwa?

Because the official regulatory labeling for Tears Daehwa is not publicly available in authoritative government databases, specific storage, handling, and disposal instructions are undefined. All drug products, however, must be stored according to their labeled conditions to maintain quality, safety, and effectiveness.

• Storage and Handling: Typically, medications require defined temperature limits (e.g., room temperature or refrigeration) and protection from light or moisture. Always keep the medication in its original container and ensure the cap is tightly closed.
• Stability: If the product is a solution, its in-use stability, or time limit for use after opening, will be strictly defined on the label. This limit must be followed to avoid using a contaminated or ineffective product.
• Disposal: Do not pour unused medicine down a sink or flush it down the toilet unless the manufacturer's official labeling explicitly instructs you to do so. Unused medication should be disposed of in accordance with local environmental and hazardous waste regulations, often through community drug take-back programs.